"Transformative" Dupilumab Set For Third Quarter Filing In Atopic Dermatitis
This article was originally published in The Pink Sheet Daily
Executive Summary
SOLO studies are "first Phase III studies of a systemic therapy to demonstrate a significant improvement in moderate-to-severe atopic dermatitis."
You may also be interested in...
Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval
CEO Olivier Brandicourt says Sanofi's Le Train, France, fill-and-finish facility should be back in FDA’s good graces before the PDUFA goal date for another Sanofi antibody, dupilumab.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.